Organization | Trimeris

Trimeris Report issue

Contributed to NME For profit Phase 2 Phase 4

Founded: Durham NC United States (1993)

Status: Acquired by Synageva Biopharma (2011) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial

1999

NCT00002239

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2007

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (8)

abacavir (ziagen) (2 trials)

atazanavir (reyataz) (1 trial)

darunavir (prezista) (1 trial)

enfuvirtide (fuzeon) (11 trials)

fosamprenavir (lexiva) (1 trial)

lamivudine (epivir) (1 trial)

lopinavir (Kaletra) (1 trial)

ritonavir (Norvir) (2 trials)

Drugs in Phase 2 Trials (3)

amprenavir (agenerase) (1 trial)

efavirenz (sustiva) (1 trial)

tifuvirtide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 4)

HIV Infections (Phase 4)

HIV Seropositivity (Phase 1)

Infections (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 11